A Consensus on the Clinical Prevention of Alzheimer's Disease: Evidence from the Chinese Expert Panel on the Granulocyte Colony-Stimulating Factor (G-CSF) Receptor

• • G-CSF administration in AD models reduced amyloid-beta plaque burden by 30-40% and improved cognitive performance in Morris water maze tests by 25% (p<0.05), suggesting disease-modifying potential. • • G-CSF treatment increased hippocampal neurogenesis by 2.5-fold and upregulated synaptic proteins (e.g., PSD-95) by 1.8-fold, indicating structural and functional neuroplasticity enhancement. • • In a phase II trial, G-CSF (10 μg/kg/day for 5 days) was well-tolerated with no severe adverse events; a 12-month follow-up showed a 15% slower decline in ADAS-Cog scores compared to placebo, though not statistically significant (p=0.08). • • The consensus recommends G-CSF as a preventive strategy for individuals with mild cognitive impairment (MCI) and high AD risk, with a target absolute neutrophil count (ANC) of 10,000-20,000/μL to balance efficacy and safety.